Scarica l'app Stockscreener
25.64
1.16%
-0.30
Dopo l'orario di chiusura:
25.30
-0.34
-1.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$25.94
Aprire:
$26.01
Volume 24 ore:
1.17M
Relative Volume:
0.72
Capitalizzazione di mercato:
$5.22B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-9.7863
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
+6.57%
1M Prestazione:
-0.66%
6M Prestazione:
+68.57%
1 anno Prestazione:
+33.40%
Intervallo 1D:
$25.09
$26.41
Intervallo di 1 settimana:
$24.85
$27.92
Portata 52W:
$12.72
$27.92
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.64 | 5.28B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat
Immunovant stock hits all-time high at 27.87 USD By Investing.com - Investing.com Canada
Immunovant Rides Brepocitinib Momentum Into 2026 - TipRanks
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV) - The Globe and Mail
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - MSN
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript - Insider Monkey
Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet News
Decoding Immunovant Inc (IMVT): A Strategic SWOT Insight - GuruFocus
Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation? - simplywall.st
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges - Investing.com Nigeria
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView
Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings - MarketBeat
Immunovant Q3 Earnings Call Highlights - MarketBeat
IMVT: Brepocitinib phase 2 data in cutaneous sarcoidosis showed 100% high-dose response and strong safety - TradingView
Immunovant Fiscal Q3 Loss Narrows; Shares Up Pre-Bell - marketscreener.com
Immunovant shares jump 7% as Q3 loss narrows, beats estimates By Investing.com - Investing.com Nigeria
IMMUNOVANT ($IMVT) Releases Q3 2026 Earnings - Quiver Quantitative
Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss - marketscreener.com
Immunovant's Q3 2025 Financial Results and Corporate Updates - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Immunovant (Nasdaq: IMVT) posts Q3 loss but boosts cash with $550M raise - Stock Titan
Immunovant earnings up next as Graves’ disease optimism builds By Investing.com - Investing.com Nigeria
Immunovant earnings up next as Graves’ disease optimism builds - Investing.com
Immunovant’s Upcoming Report to Spotlight Clinical Pipeline Progress - AD HOC NEWS
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Gem With 54.57% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (IMVT) Edition - Stock Traders Daily
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know - Finviz
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday - MarketBeat
Breakout Zone: What are analysts price targets for Immunovant Inc2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT) - MarketBeat
Published on: 2026-01-26 14:49:08 - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - The Manila Times
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,977 Shares - MarketBeat
(IMVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Marvel With 53% Potential Upside - DirectorsTalk Interviews
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Merger Talk: What are Immunovant Incs earnings expectationsTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Finviz
Immunovant (NASDAQ:IMVT) Stock Price Down 5.7%Should You Sell? - MarketBeat
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jan 21 '26 |
Sale |
26.03 |
1,977 |
51,461 |
197,634 |
| Stout Jay S | Chief Technology Officer |
Jan 07 '26 |
Sale |
26.53 |
1,203 |
31,914 |
199,611 |
| Van Tuyl Christopher | Chief Legal Officer |
Dec 18 '25 |
Sale |
26.91 |
10,813 |
290,943 |
149,930 |
| Roivant Sciences Ltd. | Director |
Dec 12 '25 |
Buy |
21.00 |
16,666,666 |
349,999,986 |
113,317,007 |
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):